TrialThe oncologist2024

Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.

Neal D Shore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.